Banner Default Image

Rayner Achieves Milestone Implantations in Landmark Clinical Trials in China and the USA

Share this article

Worthing, United Kingdom– August 11, 2023: Rayner, a global ophthalmic leader in Devices, Drugs and Digital, is pleased to announce the successful completion of the first implantations in two pivotal market access studies in China and the USA.

In April, Rayner received approval from the People’s Republic of China’s Ministry of Science and Technology (MOST) for the clinical trial involving Rayner’s trifocal intraocular lenses (IOLs). The Human Genetic Resource Administration of China (HGRAC) granted the necessary approval, and thefirst implantations for this study were carried out in June at The Peking University Hospital by Prof Xuemin Li. The trial, a prospective, multicentre, randomised, parallel-controlled, evaluator-masked, non-inferiority clinical trial, aims to evaluate the effectiveness and safety of Rayner’s RayOne Trifocal IOL for visual correction of aphakia patients.The completion of this study will facilitate market access for Rayner’s RayOne Trifocal technology in China.

Prof Xuemin Li shared the following statement:

“I was incredibly excited to have the opportunity to implant the RayOne Trifocal lens in the first Chinese patient as part of the NMPA registration clinical trial. It fills me with great joy to offer this amazing solution to my patients and be part of introducing this advanced technology to the Chinese market.”

Additionally, Rayner’sRayOne EMV Toricintraocular lens (IOL) received Investigational Device Exemption(IDE) approvalfrom the U.S. Food and Drug Administration (FDA) in June. The first study implantation took place atVance Thompson Vision in Sioux Falls, SD on August 10th. This clinical trial, a prospective, multicentre, randomised, masked, and active controlled study, aims to generate positive results that will support a Pre-Market Approval (PMA) submission to the FDA.

Dr Thompson commented:

“We have had a great experience with the RayOne EMV lens, and as an IDE clinical trial site, I am thrilled to offer this new toric version to my patients and contribute to introducing this remarkable technology to the US market.”

Expressing his enthusiasm about these significant milestones, Tim Clover, Rayner CEO, stated:

“The USA and China hold immense importance for us, and the accomplishments in these clinical trials mark significant progress as we expand our presence in these key markets and provide surgeons and their patients access to our most advanced technology IOLs.”